Previous 10 | Next 10 |
Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on re...
Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021 PR Newswire BOSTON , March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, deve...
Stealth BioTherapeutics (MITO) announces the promotion of Marty Redmon to the role of Chief Research & Development Officer, effective immediately.Marty has more than 25 years of experience in pharmaceutical R&D, operations, and project and functional line management. Prior t...
Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer PR Newswire BOSTON , March 16, 2021 /PRNewswire/ --...
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March PR Newswire BOSTON , March 2, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and comm...
Stealth BioTherapeutics Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy PR Newswire BOSTON , Feb. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology compa...
Today, we revisit a $2 biotech concern that's deep in "Busted IPO" territory named Stealth BioTherapeutics. The last time we took a hard look at this developmental concern was late in 2019. We update our investment thesis on this name to account for recent events in the paragraphs...
4 Penny Stocks That Traders Are Watching This Week As we turn the corner on the third week of February, there are plenty of penny stocks to watch . This week, the major penny stock winners have been biotech and many smaller technology-driven companies. This seems to be thematic with...
bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...
Comstock Holding Companies (CHCI) -15%.VerifyMe (VRME) -15% on stock offering.Neovasc (NVCN) -14% on stock offering; pared yesterday's gains on patent news.Enlivex Therapeutics (ENLV) -13% on stock offering.Salem Media Group (SALM) -13%.Limbach Holdings (LMB) ...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...